• Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
    • Scientific
    • Investors
    • Veterinary Resources
  • Join Mailing List
Volition
  • Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
Volition
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
      • Press Releases
      • Video Gallery
      • Media Toolkit
      • Downloads
    • Scientific
      • Clinical Papers & Posters
      • Presentations
      • Video Gallery
    • Investors
      • Presentations
      • Video Gallery
    • Veterinary Resources
  • Join Mailing List

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Shareholders Letters
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Shareholders Letters
  • IR Calendar
  • Presentations
  • Email Alerts
Apr 09, 2015 8:00am EDT

VolitionRx Adds Three New Laboratory Automation Systems to Expedite Sample Analysis for its Large Ongoing Clinical Trials

Mar 05, 2015 8:00am EST

VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics(R) Technology

Feb 24, 2015 8:00am EST

VolitionRx Acquires Direct Ownership of Nucleosomics® Technology Patent

Feb 17, 2015 8:00am EST

VolitionRx Limited Announces Exercise of Over-Allotment Option in Previously Announced Public Offering

Feb 12, 2015 8:00am EST

VolitionRx Limited Announces Closing of Public Offering of Common Stock

Feb 06, 2015 8:00am EST

VolitionRx Limited Prices Public Offering of Common Stock

Jan 20, 2015 5:00pm EST

VolitionRx Begins First Ovarian Cancer Detection Study

Jan 07, 2015 8:00am EST

Initial Study Demonstrates that VolitionRx NuQ® Blood Test Has 84% Accuracy in Detecting Early Stage Treatable Pancreatic Cancers

Dec 17, 2014 8:00am EST

VolitionRx to Initiate Study with University Hospital Bonn to Confirm NuQ® Test Accuracy in Lung Cancer

Nov 24, 2014 8:00am EST

VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Contact Us
  • Downloads
  • Privacy Policy
  • Disclaimer
  • Manage Cookie Preferences
Sign up to  email alerts
linkedin facebook twitter
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard

MENAC - Epigenetic Modifications of Nucleosomes Associated with Cancer

Thanks to a grant of 1.990.798€ from the European Regional Development Fund and Walloon Government, we’re taking part in the MENAC project which aims to develop innovative non-invasive tests for the early detection of different types of cancer. We’re working in partnership with Synabs to create monoclonal antibodies and develop new diagnostic and theragnostic immunoassays.